Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.54 |
| ▸ | PAH | P00439 | 1/20 | 0.47 |
| ▸ | FPGS | Q05932 | 2/20 | 0.39 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.38 |
| ▸ | GART | P22102 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19410958 | 0.85 | NOS1 (0.59) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL20375133 | 0.83 | NOS1 (0.58) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL20374993 | 0.83 | NOS1 (0.58) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL16572892 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL16564323 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL16572883 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL1858785 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL20375021 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL16572891 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| SCHEMBL16564266 | 0.82 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003804-A | Gene construct | 治疗基因有限责任公司 | 2022-09-02 | — | — | CN | claimed |
| EP-4013858-A1 | GENETIC CONSTRUCT | Healing Genes LLC (US) | 2022-06-22 | — | — | EP | claimed |
| CN-119925601-A | Application of tetrahydrobiopterin pathway as target in anti-QDPR deletion type tumor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-05-06 | — | — | CN | disclosed |
| CN-119317441-A | Alpha 1-antitrypsin for the treatment of diseases or conditions of the nervous system such as chronic inflammatory demyelinating polyneuropathy | 阿格罗尼克斯股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118460586-A | Overexpression vector, cofactor-independent 5-HTP synthetic strain, method and application | 天津科技大学 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023215819-A2 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-116735739-A | Method for rapidly detecting neopterin, biopterin, pterin and 7-biopterin in urine | 广州市妇女儿童医疗中心 | 2023-09-12 | — | — | CN | disclosed |
| CN-115003804-A | Gene construct | 治疗基因有限责任公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-105829541-B | Microorganisms producing benzylisoquinoline alkaloid (BIA) precursors and methods of making and using the same | 小利兰·斯坦福大学托管委员会 | 2022-08-12 | — | — | CN | disclosed |
| EP-4013858-A1 | GENETIC CONSTRUCT | Healing Genes LLC (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114302951-A | Methods for increasing production of morphinan alkaloids and derivatives | 安思雅公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20120185226-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GENOMATICA, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012027533-A1 | SELECTABLE MARKERS AND RELATED METHODS | GT LIFE SCIENCES, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2401696-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT Life Sciences, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010098865-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT LIFE SCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| US-7504095-B2 | 2,10-dioxo,2,12,12-trihydroxy,8-amino-4,4a,5a,6,9,10,11,11a,12,12a-decahydropterino(6',7':5,6)pyrano(2,3-d)-1,3,2-dioxaphosphorin | TECHNISCHE UNIVERSITAET BRAUNSCHWEIG (DE) | 2009-03-17 | — | — | US | disclosed |
| US-20070037250-A1 | 2,10-dioxo,2,12,12-trihydroxy,8-amino-4,4a,5a,6,9,10,11,11a,12,12a-decahydropterino(6',7':5,6)pyrano(2,3-d)-1,3,2-dioxaphosphorin | PHOENIX TISSUE REPAIR, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | NOS1 107/4885CASP7 3275/4885HSD17B10 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.